1 2 Title: Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme Inhibitors and 3 Angiotensin II Receptor Blockers, in a sample of infected Italian citizens. 4 5 **Short title**: Predictors of severe or lethal COVID-19. 6 Authors: Francesca Bravi 1[¶]; Maria Elena Flacco ²¶; Tiziano Carradori ¹; Carlo Alberto Volta, ^{1,3}; Giuseppe 7 Cosenza ⁴; Aldo De Togni ⁴; Cecilia Acuti Martellucci ⁵; Giustino Parruti ⁶; Lorenzo Mantovani ⁷; Lamberto 8 9 Manzoli 1,2 *. 10 11 **Affiliations**: 12 ¹ "Sant'Anna" University Hospital of Ferrara, Italy; ² Department of Medical Sciences, University of Ferrara, Italy: 13 ³ Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Italy; 14 15 ⁴ Local Health Authority of Ferrara, Italy; ⁵ Department of Biomedical Sciences and Public Health, University of the Marche Region, Ancona, Italy; 16 17 ⁶ Local Health Authority of Pescara, Italy; 18 ⁷ School of Medicine and Surgery, University Bicocca, Milan, Italy. 19 20 These authors equally contributed to the present work. 21 22 23 * Corresponding author 24 Email: lmanzoli@post.harvard.edu (La.M.)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

blockers; case-control; Italy.

Aims: This retrospective case-control study was aimed at identifying potential independent predictors of severe/lethal COVID-19, including the treatment with Angiotensin-Converting Enzyme inhibitors (ACEi) and/or Angiotensin II Receptor Blockers (ARBs). Methods and Results: All adults with SARS-CoV-2 infection in two Italian provinces were followed for a median of 24 days. ARBs and/or ACEi treatments, and hypertension, diabetes, cancer, COPD, renal and major cardiovascular diseases (CVD) were extracted from clinical charts and electronic health records, up to two years before infection. The sample consisted of 1603 subjects (mean age 58.0y; 47.3% males): 454 (28.3%) had severe symptoms, 192 (12.0%) very severe or lethal disease (154 deaths; mean age 79.3 years; 70.8% hypertensive, 42.2% with CVD). The youngest deceased person aged 44 years. Among hypertensive subjects (n=543), the proportion of those treated with ARBs or ACEi were 88.4%, 78.7% and 80.6% among patients with mild, severe and very severe/lethal disease, respectively. At multivariate analysis, no association was observed between therapy and disease severity (Adjusted OR for very severe/lethal COVID-19: 0.87; 95% CI: 0.50-1.49). Significant predictors of severe disease were older age (with AORs largely increasing after 70 years of age), male gender (AOR: 1.76; 1.40-2.23), diabetes (AOR: 1.52; 1.05-2.18), CVD (AOR: 1.88; 1.32-2.70) and COPD (1.88; 1.11-3.20). Only gender, age and diabetes also predicted very severe/lethal disease. Conclusion: No association was found between COVID-19 severity and treatment with ARBs and/or ACEi, supporting the recommendation to continue medication for all patients unless otherwise advised by their physicians. Key words: SARS-CoV-2; COVID-19; Angiotensin-converting enzyme inhibitors; Angiotensin II receptor

Introduction

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Novel coronavirus disease (COVID-19) is spreading worldwide, and has caused over 250,000 deaths so far [1]. The mortality rate varies widely by age and across individuals, ranging from 0.2% among healthy, young-adults, to >10% among older persons with pre-existing conditions [1]. Although the pharmacological treatment was not assessed, the first observational studies on patients with severe disease reported a high prevalence of comorbidities that are often treated with angiotensin converting enzyme (ACE) inhibitors, such as cerebrovascular diseases, coronary heart disease, hypertension and diabetes [2-4]. Observing that human pathogenic coronaviruses bind their target cells through angiotensinconverting enzyme 2 (ACE2) [5], and that the expression of ACE2 is substantially increased in diabetics and patients who are treated with ACE inhibitors and angiotensin II type-I receptor blockers (ARBs) [5, 6], Fang and colleagues hypothesized that the increased expression of ACE2 would facilitate infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), thus the hypertension treatment with ACE2stimulating drugs, as well as ACE2 polymorphisms, might increase the risk of developing severe COVID-19 [7]. Consequently, this would lead to a serious conflict regarding treatment, because ACE2 reduces inflammation and has been suggested as a potential new therapy for inflammatory lung diseases, cancer, diabetes, and hypertension [7-11]. In the wake of two preliminary cohort studies reporting a lower [12] or similar [13] COVID-19 mortality among inpatients hypertensive subjects treated with ARBs and ACE inhibitors, the potential predictors of COVID-19 and of disease severity, including anti-hypertensive medications, were recently analyzed by three observational studies [14-16]. No increased risk emerged from the use of ARBs or ACE inhibitors; however, the role of other potentially linked predictors, including age and cardiovascular comorbidities [7, 17, 18], differed across the population analyzed, and still requires confirmation. We have performed a case-control study on all SARS-CoV-2 infected subjects diagnosed in two Italian provinces, retrieving admission and pharmacological data up to two years before infection, in order to confirm the potential independent predictors of severe/lethal COVID-19, including treatment with ACE inhibitors and/or ARBs.

Materials and Methods

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

This case-control, retrospective study compared the proportion of subjects treated with ARBs and/or ACE inhibitors among three groups of subjects with SARS-CoV-2 infection: (a) asymptomatic infection or mild disease, defined as fever or malaise plus at least one of the followings: sore throat, muscle pain, shortness of breath, dry cough, headache, conjunctivitis, and diarrhea [19], with no hospital admission; (b) severe disease, requiring hospital admission, not in an intensive care unit: (c) very severe or lethal disease, requiring admission in an intensive care unit and/or causing death. The sample includes all subjects with diagnosis of infection made in the Province of Ferrara, up to April 2, and the Province of Pescara, Italy, up to April 24, 2020, by the Central Laboratory of the University Hospital of Ferrara or the Central Laboratory of the Pescara Hospital (and confirmed by the National Institute of Health). The data on background pharmacological treatment up to the previous two years (January 1, 2018) were obtained from the National database of drug prescription, and integrated with clinical chart information for hospitalized subjects. Data have been collected on the following drugs: ACE inhibitors (ATC classes: C09A and C09B), ARBs (C09C and C09D), and insulin or other anti-diabetic drugs (A10). Information on age, gender, and pre-existing conditions of all subjects were obtained through data-linkage with hospital discharge abstracts (Italian SDO), which have been queried from the day of the diagnosis until January 1st, 2015. All admission data have been revised manually by two physicians (LM and MEF) and the following conditions have been included in the analyses: malignant tumors, major cardiovascular diseases (heart failure, myocardial infarction and stroke - CVD), type II diabetes, renal disease and chronic obstructive pulmonary diseases (COPD, bronchitis, pneumonia, asthma, and emphysema). The study complies with the Declaration of Helsinki, the research protocol was approved by the Ethics Committee of the Emilia-Romagna Region (code 287, approved on March 24, 2020), and the requirement for informed consent was waived because of the retrospective and pseudo-anonymized nature of the data. First, the differences across groups with mild, severe or very severe/lethal disease were evaluated using t-test (for continuous variables) and Mantel-Haenzsel chi-squared test for categorical ones. A sample restricted to hypertensive subjects was used to compare the subjects treated and untreated with ACE inhibitors or ARBs.

Multivariate logistic regression was used to investigate the potential independent predictors of severe or very severe/lethal COVID-19. Four models were built, two were restricted to hypertensive subjects (A and B), and two included the total sample (Models C and D) and. Models A and C were fit to predict severe or very severe disease (grouped together), while Models B and D to predict very severe/lethal disease only (and repeated to predict death, with similar results, which have not been shown to avoid redundancy). All recorded variables were included a priori in all models, with the exception of treatments with ACE inhibitors and ARBs, that were excluded from Models C and D because of multicollinearity with hypertension. Standard diagnostic procedures were adopted to check all models validity: influential observation analysis (Dbeta, change in Pearson chi-square and similar), multicollinearity, interaction terms, Hosmer-Lemeshow test for the goodness of fit and C statistic (area under the Receiving Operator Curve). Statistical significance was defined as a two-sided p-value<0.05, and all analyses were carried out using Stata, version 13.1 (Stata Corp., College Station, TX, 2014).

Results

The sample consisted of 1603 subjects (mean age 58.0y; 47.3% males): 454 (28.3%) had severe symptoms, 192 (12.0%) very severe or lethal disease (Table 1). 154 subjects deceased (mean age 79.3 years; 54.6% males); of them, 70.8% were hypertensive, 42.2% were diagnosed a CVD; 27.9% diabetics. Twenty subjects with very severe disease were younger than 60 years; the youngest being a male aged 33 years. Of those deceased, eight were younger than 60 years, and the youngest was a female aged 44 years.

At univariate analysis, as compared to the subjects with mild disease, those with severe or very severe/lethal disease were significantly more likely to be older, diabetics, hypertensive, diagnosed with COPD, CVD, and renal disease, and treated with ARBs and/or ACE inhibitors (all p<0.05). Among hypertensive subjects (n=543), however, the proportion of those treated with ARBs or ACE inhibitors were higher among those with asymptomatic/mild disease (88.4%, versus 78.7% and 80.6% among patients with severe and very severe/lethal disease, respectively - Table 1; Figure 1).

129 Table 1. Characteristics of the sample.

Variables	Overall sample (n=1603)	Mild (n=957)	Severe (n=454)	Very severe/lethal (n=192)	p ^A	p ^B	p ^C
Mean age in years (SD)	58.0 (20.9)	50.4 (20.2)	66.4 (16.9)	76.2 (12.9)	< 0.001	< 0.001	< 0.001
Male gender, %	47.3	42.5	53.1	57.3	< 0.001	< 0.001	0.3
Diabetes, %	12.1	6.8	16.5	28.1	< 0.001	< 0.001	0.001
COPD, %	6.0	2.9	9.2	14.1	< 0.001	< 0.001	0.070
Cancer, %	7.6	5.1	10.1	14.1	< 0.001	< 0.001	0.2
Major cardiovascular diseases ^D , %	16.1	6.9	26.9	36.5	< 0.001	< 0.001	0.015
Renal disease, %	5.4	2.4	8.8	12.0	< 0.001	< 0.001	0.2
Hypertension, %	33.9	21.6	45.6	67.2	< 0.001	< 0.001	< 0.001
Antihypertensive treatment with: - ACE inhibitors, %	15.7	11.2	19.4	29.2	< 0.001	<0.001	0.006
- ARBs, % - ACE inhibitors or ARBs, %	14.2 28.1	9.0 19.1	19.8 35.9	27.1 54.2	<0.001 <0.001	<0.001 <0.001	0.042 <0.001
Sample restricted to hypertensive subjects	(n=543)	(n=207)	(n=207)	(n=129)			
Antihypertensive treatment with: - ACE inhibitors, % - ARBs, % - ACE inhibitors or ARBs, %	46.2 42.0 82.9	51.7 41.6 88.4	42.5 43.5 78.7	43.4 40.3 80.6	0.061 0.7 0.008	0.14 0.8 0.049	0.9 0.6 0.7

A Mild versus severe subjects. B Mild versus very severe subjects; C Severe versus very severe subjects. C Congestive heart failure, myocardial infarction, or stroke. COPD = Chronic obstructive pulmonary diseases. ACE = Angiotensin-Converting Enzyme. ARBs = Angiotensin II Receptor Blockers.

Figure 1. Treatment with ARBs or ACE inhibitors by COVID-19 severity among hypertensive subjects (horizontal bars are referred to 95% Confidence Intervals).

In multivariable analyses restricted to hypertensive subjects (Models A and B, Table 2), the treatment with ARBs and/or ACE inhibitors never increased the likelihood of severe or very severe/lethal disease (all p>0.4).

Table 2. Logistic regression model predicting severe or very severe/lethal COVID-19 syndrome (grouped together, Model A) or very severe/lethal disease only (Model B), in the sample restricted to hypertensive subjects.

Antihypertensive drugs:	(A) Severe or very severe/lethal OR (95% CI)	p*	(B) Very severe/lethal OR (95% CI)	p*
- ACE Inhibitors	0.70 (0.44-1.13)	0.15	0.82 (0.49-1.36)	0.4
- ARBs	0.91 (0.56-1.47)	0.7	0.83 (0.50-1.40)	0.5
- ACE Inhibitors or ARBs *	0.58 (0.34-1.01)	0.056	0.87 (0.50-1.49)	0.6

ACE = Angiotensin-Converting Enzyme. ARBs = Angiotensin II Receptor Blockers. OR = odds ratio. CI = Confidence interval.

The significant predictors of severe disease were male gender (Adjusted Odds Ratio - AOR: 1.76; 95% Confidence Interval - CI: 1.40-2.23), diabetes (AOR: 1.52; 1.05-2.18), CVD (AOR: 1.88; 1.32-2.70) and COPD (1.88; 1.11-3.20), and older age, which showed an exponential increase after 70 years: compared with the subjects younger than 50 years, the AORs of those aged 70-79 and ≥80 years were 5.72 (3.81-8.58) and 9.06 (6.04-13.6), respectively (Model C; Table 3). Only male gender, older age and diabetes also predicted very severe/lethal disease (Model D; Table 3).

All estimates have been adjusted for age, gender, diabetes, major cardiovascular diseases, COPD, cancer and renal diseases.

^{*} Models A and B have been repeated including ACE or ARBs treatment, grouped, with no substantial changes for other independent variables.

Table 3. Logistic regression model predicting severe or very severe/lethal COVID-19 syndrome (grouped together, Model C) or very severe/lethal disease only (Model D), in the total sample (n=1603).

Variables	(C) Severe or very severe/lethal OR (95% CI)	p*	(D) Very severe/lethal OR (95% CI)	p*
Male gender	1.76 (1.40-2.23)	< 0.001	1.69 (1.20-2.37)	0.003
Age class, in years - <50 (Ref. cat.)	1		1	
- 50-59.9	2.36 (1.68-3.32)	< 0.001	3.92 (1.48-10.3)	0.006
- 60-69.9	3.51 (2.43-5.07)	< 0.001	11.4 (4.63-28.1)	< 0.001
- 70-79.9	5.72 (3.81-8.58)	< 0.001	16.5 (6.66-40.9)	< 0.001
- ≥80	9.06 (6.04-13.6)	< 0.001	27.1 (11.1-66.3)	< 0.001
Diabetes	1.52 (1.05-2.18)	0.025	1.58 (1.06-2.34)	0.023
Hypertension	1.10 (0.82-1.47)	0.5	1.39 (0.94-2.05)	0.097
Major cardiovascular diseases **	1.88 (1.32-2.70)	0.001	1.05 (0.71-1.56)	0.8
Cancer	1.26 (0.81-1.95)	0.3	1.11 (0.67-1.82)	0.7
COPD	1.88 (1.11-3.20)	0.020	1.44 (0.84-2.47)	0.2
Renal disease	1.58 (0.90-2.76)	0.11	1.13 (0.64-1.99)	0.7

COPD = Chronic obstructive pulmonary diseases. OR = odds ratio. CI = Confidence interval. ACE = Angiotensin-Converting

Discussion

The main findings of this retrospective, observational study, are the following: first, it is confirmed that, among hypertensive subjects, the use of ACE inhibitors or ARBs up to two years preceding SARS-CoV-2 infection did not affect the severity of COVID-19. Second, older age, male gender, diabetes, and the presence of COPD or CVD were independent predictors of severe disease, with a sharp increase of risk among subjects older than 70 years. Third, only older age, male gender and diabetes were associated with a higher likelihood of very severe/lethal disease.

Several hypotheses have been made on the association between COVID-19 progression and treatment with ACE inhibitors and ARBs [8-10, 20, 21]. On one side, some asked whether the therapy should be discontinued during SARS-Cov-2 pandemic [7, 22] because of a strong association between hypertension

Enzyme. ARBs = Angiotensin II Receptor Blockers.

^{*} Treatments with ACE inhibitors and ARBs have not been included in both models because of multicollinearity with hypertension. ** Heart failure, myocardial infarction, or stroke.

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

and disease severity (although the pharmacological treatment were not assessed) [2-4], and based on the hypothesis that: (a) ACE2 up-regulation mediated by ARBs (and, to a lesser extent, by ACE inhibitors) might increase patients' susceptibility to SARS-CoV-2 entry into host cells and further viral propagation [20], (b) virus binding to ACE2 might reduce its activity, thus leading to increased levels of Angiotensin II and consequent pulmonary vasoconstriction, inflammation and oxidative organ damage, and increased risk of acute lung injury [8]. On the opposite side, other scientists suggested that, other than being harmful, ARBs and ACE inhibitors use in patients with cardiovascular risk factors and known or suspected COVID-19 may even exert a beneficial effect, as ACE2 up-regulation could increase the conversion of Angiotensin II to Angiotensin-(1-7), a peptide with potentially protective anti-inflammatory properties [20, 21]. Recently, three large observational studies based upon inpatient only [14] or in- and outpatient electronic health records [15, 16] examined the association between antihypertensive medications and the risk of COVID-19 and/or a severe/lethal disease: our results substantially confirm these previous findings and, concordantly, no increased risk emerged with ACE inhibitors and/or ARBs use. Of note, Mehra et al [14], after controlling for age, gender, current smoke and comorbidities, found similar death rates among COVID-19 patients using ARBs, and even lower death rates among ACE inhibitors users. The latter results, however - although in line with a previous observational analysis on Chinese in-hospital COVID-19 subjects [12], are based upon hospitalized patients only, may be due to unmeasured confounding and, in the absence of randomized evidence, should be considered only preliminary [23]. Our study, likewise Mancia et al [15] and Reynolds at al [16], included all infected subjects (either hospitalized or not), retrieved all medications and admissions from electronic health records, and evaluated the disease progression beyond mortality. Concordantly, all these findings confirm those from preliminary Chinese cohorts [12, 19] and strongly support the statements of several experts [24, 25] and scientific societies, including the European Medicines Agency [26], the European Society of Cardiology [27], and the American Heart Association [28], who recommend continuation of ARBs or ACE inhibitors medication for all patients, unless otherwise advised by their physicians. With regard to the role of the other risk factors that have been suggested for severe COVID-19, including age, male gender, hypertension, diabetes, COPD, and major cardiovascular diseases, it has been correctly argued that, so far, available data were unadjusted, thus the relative importance of underlying health

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

conditions was unclear [9, 17]. In this study, we found support for a potential role of gender, diabetes, COPD and CVD, beyond age, in COVID-19 progression to a severe disease, whereas only gender and diabetes significantly increased the risk of a lethal or very severe outcome. Thus, the present study confirms prior findings on the independent relationship of older age and male gender with death [14], and of COPD with progression towards severe disease [15]. Instead, at least two issues may have influenced the conflicting results on the role of CVD and COPD in predicting very severe/lethal disease (an association showed in some prior populations [14] - but lacking in the present as well as in other recent findings [15]): first, the relatively small sample of the present study; second, a marked difference in the population here enrolled, as compared to previous studies which included randomly selected SARS-CoV2 negative subjects as controls [15], or hospitalized-only patients [14]. Given the present scenario, further population-based cohort studies, with longer follow-up are clearly needed [17] to clarify these findings. In addition to a relatively small sample, another limitation of the present study is the lack of tobacco smoking and body mass index among the variables that have been recorded, because we could not extract such information for half of the deceased subjects, as well as for many of those that were not hospitalized. In conclusions, the present study did not find any association between COVID-19 severity and treatment with ARBs, ACE inhibitors, or both, and confirms previous findings in supporting the recommendation of several scientific societies to continue ARBs or ACE inhibitors medication for all patients, unless otherwise advised by their physicians, who should thus be reassured. The adjusted analyses substantially confirm prior reports, indicating that the risk of severe or lethal COVID-19 largely and significantly increases among the elderly, males, diabetics, and those with COPD or major cardiovascular diseases.

218 219 Conflicts of interest: None declared. 220 Authors' contribution: Conceptualization, F.B., M.E.F., T.C. and La.M.; methodology, C.A.V., G.C., 221 222 A.D.T., C.A.M., G.P., Lo.M., M.E.F. and La.M.; validation, T.C., G.P., Lo.M., C.A.V., and L.M.; formal 223 analysis, F.B., C.A.M., M.E.F. and La.M.; investigation, C.A.V., G.C., A.D.T., G.P., and C.A.M.; data 224 curation, F.B., M.E.F., and La.M.; writing—original draft preparation, M.E.F. and La.M.; writing—review 225 and editing, F.B., T.C., C.A.V., G.C., A.D.T., G.P., Lo.M.; supervision, T.C. and La.M.; project 226 administration, F.B. and T.C. All authors have read and agreed to the published version of the manuscript. 227 La.M. takes responsibility for the integrity of the work as a whole. 228 229 Access to data: The complete dataset used in this work is available in Appendix S1.

References

230

- 231 1. COVID-19 Coronavirus Outbreak [Internet]. Dadax. 2020 [cited March 14, 2020]. Available from:
- 232 https://www.worldometers.info/coronavirus/.
- 233 2. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients
- with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
- 235 Lancet Respir Med. 2020. Epub 2020/02/28. doi: S2213-2600(20)30079-5 [pii]
- 236 10.1016/S2213-2600(20)30079-5. PubMed PMID: 32105632.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus
- 238 Disease 2019 in China. The New England journal of medicine. 2020. Epub 2020/02/29. doi:
- 239 10.1056/NEJMoa2002032. PubMed PMID: 32109013.
- 240 4. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140
- patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. Epub 2020/02/23. doi:
- 242 10.1111/all.14238. PubMed PMID: 32077115.
- 243 5. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from
- Wuhan: An analysis based on decade-long structural studies of SARS. J Virol. 2020. Epub 2020/01/31. doi:
- 245 JVI.00127-20 [pii]
- 246 10.1128/JVI.00127-20. PubMed PMID: 31996437.
- 247 6. Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: Physiological
- relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res.
- 249 2017;125(Pt A):21-38. Epub 2017/06/18. doi: S1043-6618(17)30178-0 [pii]
- 250 10.1016/j.phrs.2017.06.005. PubMed PMID: 28619367; PubMed Central PMCID: PMC5607101.
- Fang I, Karakiulakis, G., Roth, M. . Are patients with hypertension and diabetes mellitus at increased
- risk for COVID-19 infection? Lancet Respir Med. 2020; [epub ahead of print]. Epub March, 11, 2020. doi:
- 253 https://doi.org/10.1016/PII.
- 8. Bavishi C, Maddox TM, Messerli FH. Coronavirus Disease 2019 (COVID-19) Infection and Renin
- Angiotensin System Blockers. JAMA Cardiol. 2020. Epub 2020/04/04. doi: 10.1001/jamacardio.2020.1282.
- 256 PubMed PMID: 32242890.
- 257 9. Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin
- 258 Receptor Blockers: What Is the Evidence? JAMA. 2020. Epub 2020/03/26. doi: 10.1001/jama.2020.4812.
- 259 PubMed PMID: 32208485.
- 260 10. Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19. BMJ.
- 261 2020;369:m1313. Epub 2020/04/04. doi: 10.1136/bmj.m1313. PubMed PMID: 32241880.
- 262 11. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-
- 263 Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. The New England journal of
- 264 medicine. 2020. Epub 2020/04/01. doi: 10.1056/NEJMsr2005760. PubMed PMID: 32227760; PubMed
- 265 Central PMCID: PMC7121452.

- 266 12. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of Inpatient Use of Angiotensin
- 267 Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With
- 268 Hypertension Hospitalized With COVID-19. Circ Res. 2020. Epub 2020/04/18. doi:
- 269 10.1161/CIRCRESAHA.120.317134. PubMed PMID: 32302265.
- 270 13. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With
- 271 Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019
- 272 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020. Epub 2020/04/24. doi:
- 273 10.1001/jamacardio.2020.1624. PubMed PMID: 32324209.
- 274 14. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and
- 275 Mortality in Covid-19. N Engl J Med. 2020. Epub 2020/05/02. doi: 10.1056/NEJMoa2007621. PubMed
- 276 PMID: 32356626.
- 277 15. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System
- 278 Blockers and the Risk of Covid-19. N Engl J Med. 2020. Epub 2020/05/02. doi: 10.1056/NEJMoa2006923.
- 279 PubMed PMID: 32356627.
- 280 16. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-Angiotensin-
- 281 Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020. Epub 2020/05/02. doi:
- 282 10.1056/NEJMoa2008975. PubMed PMID: 32356628.
- 283 17. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ.
- 284 2020;368:m1198. Epub 2020/03/29. doi: 10.1136/bmj.m1198. PubMed PMID: 32217618.
- 285 18. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in
- 286 Relation to COVID-19 in Italy. JAMA. 2020. Epub 2020/03/24. doi: 10.1001/jama.2020.4683
- 287 2763667 [pii]. PubMed PMID: 32203977.
- 288 19. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment
- Coronavirus (COVID-19). 2020. Epub 2020/03/10. doi: NBK554776 [bookaccession]. PubMed PMID:
- 290 32150360.
- 291 20. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-
- 292 Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020. Epub
- 293 2020/04/01. doi: 10.1056/NEJMsr2005760. PubMed PMID: 32227760; PubMed Central PMCID:
- 294 PMC7121452.
- 295 21. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19
- 296 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension.
- 297 2020:HYPERTENSIONAHA12015082. Epub 2020/03/27. doi: 10.1161/HYPERTENSIONAHA.120.15082.
- 298 PubMed PMID: 32208987.
- 299 22. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol.
- 300 2020;17(5):259-60. Epub 2020/03/07. doi: 10.1038/s41569-020-0360-5
- 301 10.1038/s41569-020-0360-5 [pii]. PubMed PMID: 32139904.

- 302 23. Jarcho JA, Ingelfinger JR, Hamel MB, D'Agostino RB, Sr., Harrington DP. Inhibitors of the Renin-
- 303 Angiotensin-Aldosterone System and Covid-19. N Engl J Med. 2020. Epub 2020/05/02. doi:
- 304 10.1056/NEJMe2012924. PubMed PMID: 32356625.
- 305 24. Kuster GM, Osswald S. Switching antihypertensive therapy in times of COVID-19: why we should
- wait for the evidence. European heart journal. 2020. Epub 2020/04/24. doi: 10.1093/eurheartj/ehaa335.
- 307 PubMed PMID: 32324223.
- 308 25. Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARS-CoV2: should
- inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? European heart journal.
- 310 2020. Epub 2020/03/21. doi: 10.1093/eurheartj/ehaa235. PubMed PMID: 32196087.
- 311 26. European Medicines A. EMA advises continued use of medicines for hypertension, heart or kidney
- 312 disease during COVID-19 pandemic2020 April 20, 2020. Available from:
- 313 https://www.ema.europa.eu/en/news/ema-advises-continued-use-medicines-hypertension-heart-kidney-
- 314 disease-during-covid-19-pandemic.

- 315 27. European Society of C. Position statement of the ESC Council on Hypertension on ACE-inhibitors
- 316 and angiotensin receptor blockers.2020 April 20, 2020. Available from:
- 317 https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-
- 318 council-on-hypertension-on-ace-inhibitors-and-ang.
- 319 28. American Hearth A. Patients taking ACE-i and ARBs who contract COVID-19 should continue
- 320 treatment, unless otherwise advised by their physician 2020. Available from:
- 321 https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-
- 322 treatment-unless-otherwise-advised-by-their-physician?utm campaign=sciencenews19-
- 323 20&utm source=science-news&utm medium=phd-link&utm content=phd03-17-20.

